The effect of tadalafil on functional capacity and echocardiographic parameters in patients with repaired Tetralogy of Fallot

سال انتشار: 1397
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 137

فایل این مقاله در 6 صفحه با فرمت PDF قابل دریافت می باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

JR_RYA-14-4_006

تاریخ نمایه سازی: 2 شهریور 1401

چکیده مقاله:

BACKGROUND: Tetralogy of Fallot (TOF) is one of the most common cyanotic congenital heart diseases (CHD) in children. Various surgical procedures including palliative shunts and TOF total correction (TFTC) were done with some complications, of which, the most common is pulmonary valve regurgitation (PR). Tadalafil is a phosphodiesterase ۵ inhibitor which reduces pulmonary vascular resistance, and improves right ventricular function and vascular endothelium, and may have some beneficial effects after TFTC.METHODS: We studied ۱۸ patients with TOF and PR, with some impaired right ventricular function after TFTC. Tadalafil tablets at a dose of ۱ mg per kg (maximum ۴۰ mg) per day as a single dose was administered orally for ۸ weeks. In all patients, before and after taking tadalafil, functional class assessment, electrocardiography (ECG) changes, some echocardiographic and endothelial function parameters [flow-mediated dilation (FMD) and intima-media thickness (IMT) of carotid artery], and exercise test were determined.RESULTS: The patient’s mean age was ۱۰.۱۱ ± ۴.۰۳ years, and the mean age of operation was ۲.۵۲ ± ۱.۱۲ years. The effect of tadalafil on different echocardiographic parameters and also on tricuspid valve regurgitation (TR) and PR severity and gradient was not significant. Moreover, it had no effects on QRS duration. Tadalafil had a significant effect on improving FMD and exercise test (P = ۰.۰۱). The effect of tadalafil on echocardiographic parameters, carotid artery IMT, and ECG parameters was not significant (P > ۰.۰۵). Tadalafil was tolerated well, and the most common side effects were headache and myalgia.CONCLUSION: This study showed that tadalafil is a safe and well-tolerated drug. It might improve exercise performance, endothelial function, and functional class, and possibly could allow patients a longer period of well-being and could possibly delay the need for pulmonary valve replacement (PVR).

کلیدواژه ها:

نویسندگان

Mohammad Reza Sabri

Professor, Department of Pediatric Cardiology, Pediatric Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

Mohammad Shoja

Pediatric Cardiology Fellow, Pediatric Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

Mohsen Shoja

Department of Epidemiology, Esfarayen School of Medical Sciences, Esfarayen, Iran

Mohsen Hosseinzadeh

Pediatric Cardiology Fellow, Pediatric Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

مراجع و منابع این مقاله:

لیست زیر مراجع و منابع استفاده شده در این مقاله را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود مقاله لینک شده اند :
  • Luijnenburg SE, Helbing WA, Moelker A, Kroft LJ, Groenink M, ...
  • Allen HD. Moss and Adams' heart disease in infants, children, ...
  • Affuso F, Palmieri EA, Di Conza P, Guardasole V, Fazio ...
  • Croxtall JD, Lyseng-Williamson KA. Tadalafil: In pulmonary arterial hypertension. Drugs ...
  • Jackson KW, Butts RJ, Svenson AJ, McQuinn TC, Atz AM. ...
  • Rosano GM, Aversa A, Vitale C, Fabbri A, Fini M, ...
  • Takatsuki S, Calderbank M, Ivy DD. Initial experience with tadalafil ...
  • Sabri MR, Beheshtian E. Comparison of the therapeutic and side ...
  • Sabri MR, Zolfi-Gol A, Ahmadi A, Haghjooy-Javanmard S. Effect of ...
  • Eidem BW, O'Leary PW, Cetta F. Echocardiography in pediatric and ...
  • Meyer AA, Kundt G, Steiner M, Schuff-Werner P, Kienast W. ...
  • Jackson G. Hemodynamic and exercise effects of phosphodiesterase ۵ inhibitors. ...
  • Galie N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, ...
  • Forgue ST, Patterson BE, Bedding AW, Payne CD, Phillips DL, ...
  • Magee AG, Makhecha S, Bentley S. Risk-benefit considerations when prescribing ...
  • نمایش کامل مراجع